HRT Financial’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

HRT Financial’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-982	Closed	-$11K	–	4250
2021 Q4	$11K	Buy	+982	New	+$14.1K	﹤0.01%	3023

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

HRT Financial's NVIV Position: Q1 2022 in Review

HRT Financial sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2022, closing a stake of 982 shares — an estimated $11K sold.

HRT Financial first reported a position in NVIV in Q4 2021 and held it in 1 quarter. The position peaked at $11K in Q4 2021. 16 funds tracked by Wall St. Rank hold NVIV as of Q1 2022.

HRT Financial reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2022 after selling out during the quarter.
HRT Financial sold 982 InVivo Therapeutics Holdings Corp shares in Q1 2022, an estimated $11K.
HRT Financial first reported a position in InVivo Therapeutics Holdings Corp in Q4 2021 and held it in 1 quarter.
HRT Financial's InVivo Therapeutics Holdings Corp position peaked at $11K in Q4 2021.
16 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.